Morphabond Er is a drug owned by Ohemo Life Sciences Inc. It is protected by 2 US drug patents filed from 2016 to 2019 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 12, 2028. Details of Morphabond Er's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7955619 | Abuse resistant drugs, method of use and method of making |
Aug, 2028
(3 years from now) | Active |
| US10314788 | Pharmaceutical compositions configured to deter dosage form splitting |
Aug, 2028
(3 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Morphabond Er's patents.
Latest Legal Activities on Morphabond Er's Patents
Given below is the list of recent legal activities going on the following patents of Morphabond Er.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Correspondence Address Change Critical | 21 Dec, 2023 | US7955619 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Jun, 2022 | US10314788 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 08 Jun, 2022 | US7955619 |
| Email Notification Critical | 20 Oct, 2020 | US7955619 |
| Change in Power of Attorney (May Include Associate POA) Critical | 20 Oct, 2020 | US7955619 |
| Correspondence Address Change Critical | 15 Oct, 2020 | US7955619 |
| Email Notification Critical | 08 Sep, 2020 | US10314788 |
| Change in Power of Attorney (May Include Associate POA) Critical | 08 Sep, 2020 | US10314788 |
| Correspondence Address Change Critical | 03 Sep, 2020 | US10314788 |
| Email Notification Critical | 27 Aug, 2020 | US7955619 |
FDA has granted several exclusivities to Morphabond Er. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Morphabond Er, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Morphabond Er.
Exclusivity Information
Morphabond Er holds 1 exclusivities. All of its exclusivities have expired in 2018. Details of Morphabond Er's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-189) | Oct 02, 2018 |
US patents provide insights into the exclusivity only within the United States, but Morphabond Er is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Morphabond Er's family patents as well as insights into ongoing legal events on those patents.
Morphabond Er's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Morphabond Er's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Aug 12, 2028 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Morphabond Er Generic API suppliers:
Morphine Sulfate is the generic name for the brand Morphabond Er. 33 different companies have already filed for the generic of Morphabond Er, with Strides Pharma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Morphabond Er's generic
How can I launch a generic of Morphabond Er before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Morphabond Er's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Morphabond Er's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Morphabond Er -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 15 mg, 30 mg, 60 mg and 100 mg | 28 Jan, 2019 | 1 | 21 Aug, 2028 |
Alternative Brands for Morphabond Er
There are several other brand drugs using the same active ingredient (Morphine Sulfate) as Morphabond Er. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Alpharma Pharms |
| |
| Fresenius Kabi Usa |
| |
| King Pharms Llc |
| |
| Pacira Pharms Inc |
| |
| Zyla |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Morphine Sulfate, Morphabond Er's active ingredient. Check the complete list of approved generic manufacturers for Morphabond Er
About Morphabond Er
Morphabond Er is a drug owned by Ohemo Life Sciences Inc. Morphabond Er uses Morphine Sulfate as an active ingredient. Morphabond Er was launched by Ohemo Life in 2015.
Approval Date:
Morphabond Er was approved by FDA for market use on 02 October, 2015.
Active Ingredient:
Morphabond Er uses Morphine Sulfate as the active ingredient. Check out other Drugs and Companies using Morphine Sulfate ingredient
Dosage:
Morphabond Er is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 60MG | TABLET, EXTENDED RELEASE | Discontinued | ORAL |
| 15MG | TABLET, EXTENDED RELEASE | Discontinued | ORAL |
| 100MG | TABLET, EXTENDED RELEASE | Discontinued | ORAL |
| 30MG | TABLET, EXTENDED RELEASE | Discontinued | ORAL |